^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRGN-2009

    i
    Associations
    News

    Trials

    Company:
    Precigen
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (NCT05996523)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/07/2023
    Primary completion :
    11/01/2024
    Completion :
    11/01/2027
    CD4
    |
    Keytruda (pembrolizumab) • PRGN-2009
    HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers (20-C-0104) (NCT04432597)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/27/2023
    Initiation :
    08/11/2020
    Primary completion :
    11/22/2022
    Completion :
    11/20/2025
    CD4
    |
    TILs
    |
    bintrafusp alfa (M7824) • PRGN-2009